Literature DB >> 15301685

Hepatitis C virus infection in intravenous drug users.

J Harder1, E Walter, B Riecken, C Ihling, T M Bauer.   

Abstract

Intravenous drug use (IVDU) remains a major means of hepatitis C virus (HCV) transmission. In this study, 101 drug users were studied prospectively after cessation of IVDU. Of these, 75.8% were anti-HCV positive, and 71.4% had elevated levels of alanine aminotransferase. These levels decreased significantly within 1 month of IVDU cessation (p 0.02). Liver biopsies showed minimal or mild fibrosis in 32 (71%) of 45 subjects, and severe fibrosis in two (4.4%) subjects. Anti-HCV-positive intravenous drug users in this study presented with mild liver disease and variable stages of disease progression. Biochemical disease activity might be affected by IVDU.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15301685     DOI: 10.1111/j.1469-0691.2004.00934.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  5 in total

Review 1.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

2.  Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place.

Authors:  Holly Hagan; Enrique R Pouget; Don C Des Jarlais; Corina Lelutiu-Weinberger
Journal:  Am J Epidemiol       Date:  2008-10-09       Impact factor: 4.897

3.  Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.

Authors:  Steven Flamm; David Mutimer; Armen Asatryan; Stanley Wang; Jürgen Rockstroh; Yves Horsmans; Paul Y Kwo; Ola Weiland; Erica Villa; Jeong Heo; Edward Gane; Stephen D Ryder; Tania M Welzel; Peter J Ruane; Kosh Agarwal; Teresa I Ng; Zhenyi Xue; Sandra S Lovell; Preethi Krishnan; Sarah Kopecky-Bromberg; Roger Trinh; Federico J Mensa; David L Wyles
Journal:  J Viral Hepat       Date:  2018-12-11       Impact factor: 3.728

4.  Epidemiology and Clinical Characteristics of Individuals with Hepatitis C Virus Infection in the United States, 2017-2019.

Authors:  Nancy Reau; Mark S Sulkowski; Emmanuel Thomas; Vinay Sundaram; Qingqing Xu; Wei-Han Cheng; Steven E Marx; Oscar A Hayes; Shivaji R Manthena; Viktor Chirikov; Douglas E Dylla; Hannah Brooks; Jana M Carabino; Sammy Saab
Journal:  Adv Ther       Date:  2021-10-27       Impact factor: 3.845

5.  Antibodies to the Novel Human Pegivirus 2 Are Associated with Active and Resolved Infections.

Authors:  Kelly E Coller; Michael G Berg; Matthew Frankel; Kenn Forberg; Rita Surani; Charles Y Chiu; John Hackett; George J Dawson
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.